



Article

TPGS-Stabilized Curcumin Nanoparticles Exhibit Superior Effect on Carrageenan-Induced Inflammation in Wistar Rat

Heni Rachmawati^{1,2,*}, Dewi Safitri³, Aditya Trias Pradana⁴ and I Ketut Adnyana³

¹ Pharmaceutics Research Group, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia

² Research Center for Nanosciences and Nanotechnology, Bandung Institute of Technology, Bandung 40132, Indonesia

³ Pharmacology and Clinical Pharmacy Research Group, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia; dewi.s@fa.itb.ac.id (D.S.); ketut@fa.itb.ac.id (I.K.A.)

⁴ Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; aditya_trias@yahoo.com

* Correspondence: h_rachmawati@fa.itb.ac.id; Tel.: +62-222-504-852

Academic Editor: Leena Peltonen

Received: 4 June 2016; Accepted: 8 August 2016; Published: 16 August 2016

Abstract: Curcumin, a hydrophobic polyphenol compound derived from the rhizome of the *Curcuma* genus, has a wide spectrum of biological and pharmacological applications. Previously, curcumin nanoparticles with different stabilizers had been produced successfully in order to enhance solubility and per oral absorption. In the present study, we tested the anti-inflammatory effect of D- α -Tocopheryl polyethylene glycol 1000 succinate (TPGS)-stabilized curcumin nanoparticles in vivo. Lambda-carrageenan (λ -carrageenan) was used to induce inflammation in rats; it was given by an intraplantar route and intrapelurally through surgery in the pleurisy test. In the λ -carrageenan-induced edema model, TPGS-stabilized curcumin nanoparticles were given orally one hour before induction and at 0.5, 4.5, and 8.5 h after induction with two different doses (1.8 and 0.9 mg/kg body weight (BW)). Sodium diclofenac with a dose of 4.5 mg/kg BW was used as a standard drug. A physical mixture of curcumin-TPGS was also used as a comparison with a higher dose of 60 mg/kg BW. The anti-inflammatory effect was assessed on the edema in the carrageenan-induced paw edema model and by the volume of exudate as well as the number of leukocytes reduced in the pleurisy test. TPGS-stabilized curcumin nanoparticles with lower doses showed better anti-inflammatory effects, indicating the greater absorption capability through the gastrointestinal tract.

Keywords: curcumin; nanoparticle; inflammation; λ -carrageenan; nanoparticle permeability; Biopharmaceutical Class System (BCS) 4

1. Introduction

Curcumin, commonly called diferuloyl methane, is a hydrophobic natural polyphenolic phytoconstituent derived from the rhizomes of *Curcuma longa* Linn (Zingiberaceae). Curcumin is a major compound of curcuminoid. It has better radical scavenging and antioxidant abilities compared to demethoxycurcumin and bis-demethoxycurcumin. Curcumin is an amphipathic molecule with polar central and flanking regions that are separated by a lipophilic methine segment. It has a pKa1, pKa2, and pKa3 value of 7.8, 8.5, and 9.0, respectively for three acidic protons [1]. Curcumin has a high partition coefficient (log P) in the range of 2.3 to 2.6 [2–4]. Despite the polarity of the functional groups and the central dicarbonyl moiety, curcumin, overall, is hydrophobic. This is evidenced by its



PENGESAHAN

Dekan,

Dr. Christina Avanti, M.Si., Apt.

poor solubility in aqueous solvents and good solubility in organic solvents. Curcumin's relatively high degree of lipophilicity, due to the methine-rich segments that connect the polar regions, has various important implications on biological activities and also, on the other hand, bears several complexities in the *in vitro* and *in vivo* studies [5].

Several reports established ways to improve the solubility of curcumin in aqueous media by increasing the pH. However, changing the conditions to be more alkaline, does not yield a tremendous increase in solubility but does make it much more susceptible to degradation, i.e., it causes alkaline hydrolysis at pH 6.5 due, in part, to the formation of the phenylate anion. So, increasing the pH to dissolve curcumin is not recommended during formulation development. As solubility is one of the two key factors influencing the bioavailability and then biological activity of many active compounds, various efforts are still underway to determine a better method for improving solubility.

Curcumin is a very unique and attractive natural compound due to two contradictive issues: it is a potential therapeutic agent for a wide range of diseases, but problematic in terms of formulation and delivery development.

While the activity of curcumin against a number of disorders is highly promising, the relative bioavailability of curcumin is low [6], reaching only 1% in rats. The absorption process of curcumin is considerably low in the gastrointestinal tract which leads to trace concentrations of curcumin in serum. Ravindranath reported that detectable curcumin was found within 15 min to 20 h after oral administration [7]. Poor oral absorption of curcumin relates to this lower intrinsic activity, lower absorption rate, and high metabolism rate.

A smart, affordable technology that is acceptable for large scale production is required to solve the issues of solubility and permeability. We produced nanoparticles of curcumin by using high pressure homogenization with five distinct stabilizers [8]. A set of physical evaluations demonstrated that polyvinylpyrrolidone (PVP) and TPGS (D- α -Tocopheryl polyethylene glycol 1000 succinate) are the most appropriate stabilizers. This report describes the beneficial aspects of TPGS-stabilized curcumin nanoparticles in treating inflammatory models in animals. Various doses were evaluated to demonstrate the proof of concept on the particle size to solubility correlation. Reducing the particle size down to a nanometer scale was expected to lower the therapeutic dose while increasing the efficacy.

2. Materials and Methods

2.1. Materials

Curcumin was purchased from PT. Phytochemindo, Reksa, Bogor, Indonesia, D- α -Tocopheryl polyethylene glycol 1000 succinate (TPGS) was commercially obtained from Eastman Chemical Company, Liverpool, UK, diclofenac sodium was purchased from PT Kimia Farma, Bandung, Indonesia, λ -carrageenan was commercially obtained from Sigma-Aldrich, Singapore, NaCl 0.9% was purchased from Otsuka, Tokyo, Japan, Turk's solution was from Merck, Darmstadt, Germany, heparin was obtained commercially from Inviclot[®] (Tangerang, Indonesia). All materials used were pharmaceutical grade.

2.2. Characterization of Curcumin Nanoparticles

Both conventional curcumin and curcumin nanoparticles were characterized to confirm physical property consistency, including particle size analysis, polydispersity index, zeta potential, morphology with Scanning Electron Microscope (SEM), and curcumin nanoparticle solubility in water.

2.3. Particle Size Analysis and Zeta Potential Determination

Analysis on particle size and zeta potential were performed by using the DelsaTMNanoC instrument (Beckman Coulter[®], Brea, CA, USA). Both curcumin and curcumin nanoparticles were prepared to obtain 100 ppm suspension in water. Before measurement, the suspension was placed in

a bath sonicator for approximately 1 min to disrupt any loose-formed agglomerates. Measurement was carried out using particular equipment for particle size and zeta potential analysis.

2.4. Solubility Test of Curcumin Nanoparticles

With the same concentration, either curcumin nanoparticles (NC) or conventional curcumin-TPGS were suspended in water. Both samples were placed into an orbital shaker with the following conditions: 25 °C, 100 rpm, for 1 h. Approximately 5 mL of the solution was taken and then centrifuged for 3 min at 12,500 rpm. The samples were filtered using a 0.22 µm filter membrane to separate the insoluble compounds. Curcumin content was determined using spectrophotometric Ultra Violet/Visible (UV/Vis) at wavelength of 425 nm. Water was applied as a standard blank.

2.5. Scanning Electron Microscopy

Curcumin and curcumin nanoparticles were fixed on a brass stub and were coated by gold in vacuum conditions. The pictures were taken at an excitation voltage of 10 kV and at 500, 5000, 20,000× magnification by using a JSM-360LA Scanning Microscope (Jeol, Tokyo, Japan).

2.6. Fourier Transmission Infrared Spectroscopy (FTIR)

Analysis of Fourier Transmission Infrared Spectroscopy (FTIR) was performed with a Shimadzu FTIR Prestige 21 spectrometer (Shimadzu, Tokyo, Japan) to determine the typical functional groups in curcumin and curcumin nanoparticles. Five milligram samples were prepared with the KBr discs method (160 mg). Wave numbers scanning was conducted with the range of 400–4500 cm⁻¹ with resolution of 2 cm⁻¹.

2.7. X-ray Diffraction

The crystalline phase of both curcumin and PVP-nanocurcumin were determined by X-ray powder diffraction (XPRD) by using a Diano (Woburn, MA, USA) diffractometer with Cu-K' radiation ($\lambda = 0.1540$ nm).

2.8. Stability Study

The nanosuspensions were stored in sealed vials at different temperatures (room temperature (RT) and 4 °C) for 30 days. Samples were taken on day 0 (day of production), day 7, and day 30. Characterization was carried out for particle size by Photon Correlation Spectroscopy (PCS), Laser Diffraction (LD), and polarized light microscopy.

2.9. Animals

Specific pathogen-free male Wistar rats that were approximately 2 to 3 months of age and 150 to 200 g body weight were used for the activity study, while healthy male Webster mice with 20–30 mg body weight were used for the bio-distribution study. The animals were provided by Animal Laboratory, School Pharmacy, Bandung Institute of Technology, Bandung-Indonesia and were handled under the standard conditions of animal experimentation. Prior to use, all animals were acclimatized for seven days, fed with a standard diet, and allowed to access water ad libitum. The experiment was performed according to the ethical guidelines for investigations in animal laboratory, and approved by The Ethics Committee on Use of Animal Experimentation, School of Pharmacy, Bandung Institute of Technology, Bandung, Indonesia (3 April 2013).

2.9.1. Biodistribution Study of Curcumin Nanoparticle

The bio-distribution study was performed on ¹³¹I-labeled curcumin nanoparticles given intravenously to healthy male Webster mice (100 µCi/mouse). The bio-distribution of ¹³¹I-labeled curcumin was observed at 15 min, 1 h and 17 h after intravenous administration of the sample.

Blood and major organs were taken and the radioactivity of ^{131}I -labeled curcumin was measured on a gamma counter.

2.9.2. Experimental Design for Antiinflammatory Assay of Curcumin Nanoparticle

Two studies were carried out to evaluate the anti-inflammatory effect of TPGS-stabilized curcumin nanoparticles. These studies were differentiated based on the time of treatment: prior and post inflammatory inductions.

In the first study, the animals were divided randomly into five groups: one group was treated with TPGS 1% (control group); one group received sodium diclofenac (SD, 4.5 mg/kg BW), one group received conventional curcumin mixed with TPGS 1% (C, 60 mg/kg BW), one group received TPGS-stabilized curcumin nanoparticles (NC, 1.8 mg/kg BW), and one group received TPGS-stabilized curcumin nanoparticles (NC, 0.9 mg/kg BW). One hour prior to induction, preparation was given orally. Further, 0.05 mL of 1% λ -carrageenan in NaCl 0.9% was injected to induce paw edema via intraplantar. Paw volumes were determined using a mercury plethysmometer every hour for six hours after injection.

In the second experiment, similar groups were used, but the preparations were given post induction: 30 min, 4.5 h, and 8.5 h. The induction of inflammation was done by injection of 0.05 mL of 1% λ -carrageenan via intraplantar. Observation on paw edema was performed within 10 h after induction.

All studies were performed using one independent experiment with six animals per group.

The inflammatory response is usually quantified by increase in paw volume (edema) which is calculated by the following formula:

$$\% \text{ edema} = \frac{V_t - V_o}{V_o} \times 100\% \quad (1)$$

V_t = paw's volume at specific measurement time;

V_o = basal paw's volume before induction.

2.10. Leukocyte Migration Test (Pleuricy Test)

This measurement was conducted to study the activity of TPGS-stabilized curcumin nanoparticles in a more severe model of inflammation. There were five groups similar to the groups used for the animal study described previously, with similar doses of curcumin and curcumin nanoparticles. One hour prior to induction, the preparations were given orally. To perform this experiment, all rats were anesthetized during surgery by the injection of thiopental sodium (50 mg/kg BW, intraperitoneally). Rats were placed on their backs and the hair from the skin over the ribs of the right side was removed using animal clippers. The region was then swabbed with 70% alcohol. A small incision was made into the skin between the seventh and eighth rib. With the intercostal muscle exposed, approximately 0.1 mL of 2% λ -carrageenan suspension was injected into the pleural cavity through this incision. The injection needed to be made swiftly to avoid lung injury. Further, the wound was closed by silk suture 5/0. Twenty-four and forty-eight hours after induction, all rats received a dosage form in accordance to their group. Seventy-two hours after the inflammatory challenge, rats were sacrificed by placing them into a carbon dioxide chamber. Subsequently, the thorax cavity was opened and the exudate collected by aspiration. The exudate was rinsed with 2 mL of NaCl 0.9% that was already mixed with a 5 iu/mL of heparin solution. Approximately 20 μL of collected exudate was then mixed with 380 μL of Turk's solution to determine the mobilized leukocyte number in the exudate using hemocytometer counting chambers. The results were converted on the basis of exudate volume.

2.11. Statistical Evaluation

All data were evaluated using one-way ANOVA followed by Least Significant Difference (LSD) post-hoc analysis by SPSS software version 15 (IBM corp., New York, NY, USA, 2006). The statistical difference was considered significant at $p < 0.05$.

3. Results

3.1. Characterization of Nanoparticles

3.1.1. Particle Size Analysis, Zeta Potential

The size, size distribution, and surface charge of the samples are presented in Table 1.

Table 1. Physical characteristics of curcumin and curcumin nanoparticles.

Parameters	Curcumin	Curcumin Nanoparticles
Particle size (nm)	2273.6	435.7
Polydispersity index	0.667	0.316
Zeta potential (mV)	-13.60	-21.20

3.1.2. Solubility Test

The profile of solubility of both curcumin-TPGS and TPGS-stabilized curcumin nanoparticles was reflected by UV/Vis spectra (Figure 1). Simply, by considering the absorbance value, the potency of nanonization is clearly indicated. As seen, the absorbance of curcumin nanoparticles at 425 nm was approximately 13 times higher than conventional curcumin.




Figure 1. Visible spectra of curcumin and curcumin nanoparticles in water at 25 °C.

3.1.3. Scanning Electron Microscope

The morphology of both conventional curcumin and curcumin nanoparticles is depicted in Figure 2.




Figure 2. Scanning Electron Microscopic analysis. (a) Curcumin 500×; (b) curcumin nanoparticles 5000×; (c) curcumin nanoparticles 20,000×.

As shown in the Figure 2, the morphology of TPGS-stabilized curcumin nanoparticle showed a more spherical shape as compared with curcumin powder with irregular shapes. Particle size of the nanoparticles was drastically decreased from microscale to nanoscale (~400 nm).

3.1.4. Fourir-Transmission Infrared Spectroscopy

Figure 3 shows the FTIR spectra of both curcumin and curcumin nanoparticles.




Figure 3. Fourir Transmission Infrared Spectroscopy (FTIR) spectra of curcumin (a) and curcumin nanoparticles (b).

It is clearly shown that the FTIR profile of curcumin is similar to curcumin after the application of high pressure to reduce the particle size of curcumin down to nanometers, except the intensity in particular on peaks at wavenumber 3000–4000 and around 1000.

3.1.5. X-ray Diffraction

The crystallinity of curcumin after the high pressure homogenization application to form nanoparticles was analysed using X-ray diffractometry. A reduction in the degree of crystallinity of curcumin nanoparticles was observed (Figure 4). In addition, no other peaks were shown on curcumin nanoparticles. This indicates that the mechanical stress applied during nanoparticle production did not result in a new structure.




Figure 4. The X-ray diffractograms of curcumin (a) and curcumin nanoparticles (b).

3.1.6. Stability Study

Figure 5 shows the particle size of curcumin nanoparticles after storage for 30 days at 4 °C and room temperature. There was no particle aggregation or crystal growth observed at either storage condition as well as no change in particle distribution size indicated by polydispersity indexed from day 0 to day 30.




Figure 5. Photon Correlation Spectroscopy (PCS) diameter and Laser Diffraction (LD) diameter $d(v)95\%$ and $d(v)99\%$ of α -Tocopheryl polyethylene glycol 1000 succinate (TPGS)-stabilized curcumin nanosuspensions as a function of days (0–30) stored at room temperature (RT, left) and at 4 °C (right).

The stability data shown in Figure 5 was confirmed by microscopic evaluation on the sample using a polarized microscope (Figure 6).




Figure 6. Polarized light micrographs (magnification 160 \times) of the nanosuspensions after 30 days of storage at 4 °C and room temperature (RT). The scale bars are 200 μ m.

3.1.7. Biodistribution Study of Curcumin Nanoparticles

The in vivo accumulation of curcumin at 15 min, 1 h, and 17 h after intravenous administration of 131 I-labeled curcumin solution to Webster mice ($n = 6$) is presented in Figure 7.




Figure 7. The accumulation profile of 131 I-labeled curcumin after intravenous administration to male healthy Webster mice.

In the first hour of observation, curcumin was mostly circulated in the blood which is available for pharmacological effect. The distribution of curcumin to kidney, lymph, lung, heart and brain was considered absent (<5%) even at the beginning phase after the preparation entered the body. The liver seems to be the main organ for curcumin metabolism.

3.2. Preventive Effect of Curcumin Nanoparticle on λ -Carrageenan-Induced Inflammation in Rats

Figure 8 presents the visual observation on λ -carrageenan-induced edema development on the rats' paws after treatment with both curcumin and curcumin nanoparticles 6 h after induction.

The quantitative analysis on percentage of edema as depicted in Figure 9 shows significant effects only when the animals were treated using curcumin nanoparticles with a dose of 1.8 mg/kg BW (30 times lower than conventional curcumin).




Figure 8. The paw volume observation at 6 h after induction: (a) Control group; (b) sodium diclofenac (SD) 4.5 mg/kg body weight (BW); (c) curcumin (C) 60 mg/kg BW; (d) nanocurcumin (NC) 0.9 mg/kg BW; (e) NC 1.8 mg/kg BW.




Figure 9. Percentage of paw edema of treated groups 1 h prior to induction. (◆) Control group; (■) SD 4.5 mg/kg BW; (▲) C 60 mg/kg BW; (●) NC 0.9 mg/kg BW; (□) NC 1.8 mg/kg BW. * Indicates statistically different than control group ($p < 0.05$). Each group consisted of six rats.

We observed statistically significant differences between the groups that received curcumin nanoparticles (1.8 mg/kg) and the control group at hours 1, 3, 4, 5, and 6 with the percentage of edema 9.22%, 36.23%, 42.28%, 36.71%, and 35.84%, respectively. The percentage of edema indicates the level of inflammation. The lower the percentage reflects the regression of inflammation. Therefore, the treatment which lowers this percentage compared to the control is considerably expressed as an anti-inflammatory effect.

3.3. Antiinflammatory Effect of Curcumin Nanoparticle on λ -Carrageenan-Induced Inflammation in Rats

Figure 10 represents the effect of curcumin after induction on the regression of edema volume in λ -carrageenan-induced rats. As shown, the standard drug sodium diclofenac showed the strongest effect reaching 10.12% at hour 10. The anti-inflammatory effect of curcumin was also displayed in a dose-dependent manner. Reduction of the particle size of curcumin demonstrated a superior effect as reflected by the decreased therapeutic dose. Curcumin in the nanometer scale (~400 nm) required a dose of 60 times less than the conventional curcumin dose to exhibit similar biological effects. The strongest effect of sodium diclofenac is indeed due to the higher dose as compared to curcumin nanoparticles (4.5 versus 1.8 mg/kg BW). We speculate that by applying a similar dose of curcumin nanoparticles to sodium diclofenac, the anti-inflammatory effect would be comparable.




Figure 10. The percentage of paw edema on treated λ -carrageenan-induced rats. (◆) control group; (■) SD 4.5 mg/kg BW treated group; (▲) C 60 mg/kg BW group; (●) NC 0.9 mg/kg BW group; and (□) NC 1.8 mg/kg BW. * Indicates statistically different than control group ($p < 0.05$). Each group consisted of six rats.

3.4. Pleurisy Test

Pleurisy is a well-known phenomenon of exudative inflammation in living organisms. Carrageenan-induced pleurisy in rats is considered to be a suitable inflammatory model in which fluid extravasation, leukocyte migration, and the various biochemical parameters can be measured in the exudate [9]. The higher values of such parameters indicate the severity of inflammation. Thus, compounds that are capable of reducing exudate formation, suppressing leukocyte migration, as well as improving biochemical properties can be proven as anti-inflammatory agents.

Table 2 presents the anti-inflammatory effect of curcumin nanoparticles in terms of the reduction in the number of leukocytes and exudate formation. A similar trend of anti-inflammatory effects to

Figure 6 was also revealed. Sodium diclofenac 4.5 mg/kg BW as a standard drug demonstrated the strongest effect.

Table 2. The effects of treatments on the pleurisy test.

Group (N = 6)	Volume of Exudate (mL)	The Number of Leukocytes ($\times 10^8$ /mL)
Control	4.80 \pm 0.80	5.65 \pm 1.77
SD 4.5 mg/kg BW	2.18 \pm 0.21 ^a	1.36 \pm 0.12 ^a
C 60 MG/KG BW	3.25 \pm 0.29 ^{ab}	2.89 \pm 1.05 ^{ab}
NC 0.9 mg/kg BW	3.25 \pm 0.82 ^{ab}	2.34 \pm 1.16 ^a
NC 1.8 mg/kg BW	2.95 \pm 0.63 ^{ab}	1.73 \pm 1.08 ^a

The values represent mean \pm standard deviation. ^a: Significantly different than the control group ($p < 0.05$); ^{ab}: significantly different than the sodium diclofenac-treated group ($p < 0.05$). SD: sodium diclofenac; C: curcumin; NC: nanocurcumin.

4. Discussion

We successfully developed curcumin nanoparticles and completed a physical characterization [5]. The physical characterization of TPGS-stabilized curcumin nanoparticles such as FTIR, SEM, and X-ray Diffraction (XRD) as well as a month stability test reported here confirmed the function of TPGS as an appropriate stabilizer preventing curcumin nanoparticle agglomeration. The FTIR data suggest no structure alteration after high pressure homogenization was applied on curcumin to form nanoparticles. These data are important in regard to the biological activity of curcumin described in this report. While the XRD data suggest any reduction on the curcumin nanoparticle crystallinity may also contribute slightly to a curcumin solubility enhancement in addition to particle size reduction. Curcumin is a unique, pure bioactive compound. Curcumin is a main phenolic constituent in the *Curcuma* genus, which is broadly known to exhibit a wide range of pharmacological effects: anti-inflammation, antibacterial, antioxidant agent, and has been widely used for treating Alzheimer's disease (AD), Parkinson's disease, multiple sclerosis, epilepsy, cerebral injury, cardiovascular diseases (CVDs), cancer, allergy, asthma, bronchitis, colitis, rheumatoid arthritis, renal ischemia, psoriasis, diabetes, obesity, depression, fatigue, and acquired immune deficiency syndrome (AIDS) [10]. In particular as an anti-inflammatory, curcumin is noticeably effective both in acute and chronic inflammations as described in this report.

λ -Carrageenan used in this study, is a complex group of polysaccharides made up of repeating galactose monomers. The inflammation induced by carrageenan is considerably acute, and not only causes edema, but also hyperalgesia and erythema resulting from the action of pro-inflammatory agents such as bradykinin, histamine, tachykinins, complement and reactive oxygen, and nitrogen species [11]. Through these cascades, swollen paws due to fluid extravasation into the injection site is a clear visual manifestation, therefore, acting as a good parameter to screen the anti-inflammatory drugs. The progression of paw edema is also triggered by neutrophils which migrate to the site of injection and generate pro-inflammatory reactive oxygen as well as other species. We challenged our developed curcumin nanoparticle in different inflammatory models as most of the natural compounds have a weak therapeutic effect and require high therapeutic doses especially in severe diseases. We tested our approach to observe whether particle size reduction on curcumin down to ~ 400 nm followed by the presence of TPGS decreased the therapeutic dose of curcumin significantly in the model of chronic inflammation.

In the case of curcumin as an anti-inflammatory agent, the compound interacts with numerous molecular targets involved in the progression of inflammation. As reported previously, this interaction mediates curcumin to down-regulate various pro-inflammatory cytokines, which include interrupting formation of prostaglandin, inhibiting cyclooxygenase (COX), lipoxygenase, inducible Nitric Oxide Synthase (iNOS), and other pro-inflammatory mediators such as tumor necrosis factor (TNF- α), interleukins (IL-1, IL-2, IL-6, IL-8, IL-12) and chemokines [12–15]. As described by Heger et al. [16],

curcumin has seven different chemical properties facilitating intermolecular interactions hence association with its biomolecular targets. These include (1) H-bond donating and accepting capacity of the β -dicarbonyl moiety; (2) H-bond accepting and donating capacity of the phenylic hydroxyl residues; (3) H-bond accepting capacity of the ether residue in the methoxy groups; (4) multivalent metal and nonmetal cation binding properties; (5) high partition coefficient ($\log P$); (6) rotamerization around multiple C–C bonds; and (7) acceptor of a Michael reaction. In line with the report of Jeong et al., α,β -unsaturated diketone moiety of curcumin is a Michael reaction acceptor which is a major class of phase-II enzyme inducers [17]. This property is suggested to be responsible for stimulating HO-1 and NF- κ B suppression in cells by curcumin. The anti-inflammatory effect of both curcumin and curcumin nanoparticles reported here is suggested through those mechanisms.

The more potent anti-inflammatory effect of curcumin nanoparticles as seen in Figures 8–10 is clearly via its improved solubility. The particle size is the initial determining factor of curcumin bioavailability. Curcumin is a Biopharmaceutical Class System (BCS) 4 compound which means the solubility and permeability are problematic and influence its efficacy. Reducing the particle size of curcumin down to nanometer scale (~400 nm) as described here, enhanced its saturated solubility by 13 times (Figure 1). We suggest that the particle size is a key factor determining the ability of curcumin to cross the gut membrane. The presence of TPGS in nanoparticle formula is also considered to influence the therapeutic effect of curcumin nanoparticles which in turn effects the therapeutic dose. TPGS (D- α -Tocopheryl polyethylene glycol 1000 succinate) is a surfactant but also an absorption enhancer through P-gp inhibition. The presence of TPGS in curcumin nanoparticles provides a substantial improvement to curcumin absorption. Thus, reducing particle size of curcumin down to ~400 nm combined with TPGS, as reported here, clearly increases the potency of curcumin by 30 times compared to conventional curcumin. This increase is comparable to a standard anti-inflammatory drug sodium diclofenac. Increased bioavailability was due to a combination of increased surface area-to-volume ratio, possible micelle formation, and enhanced permeability. There is a clear relationship between the particle size and absorption enhancement with the therapeutic dose of BCS 4 drugs, including curcumin. As seen in Figures 1 and 2c, the solubility of curcumin-TPGS is far lower leading to less efficacy as compared to TPGS-stabilized curcumin nanoparticle. Clearly, improved solubility is an important initial step before the action of absorption enhancer TPGS can start. Our TPGS-stabilized curcumin nanoparticles are, therefore, promising as an alternative therapy, in particular for chronic inflammatory diseases. Well known serious side effects of frequently used oral non steroid anti-inflammatory drugs (NSAIDs) are still an issue for successful treatment in chronic inflammation.

5. Conclusions

Curcumin nanoparticles demonstrate superior anti-inflammatory effects in an animal model of acute and chronic inflammations, when given orally. It is suggested that by reducing the particle size of curcumin to nanoscale, the bio-availability is improved through enhancing the solubility. As curcumin is an active compound in the classification of BCS 4, solubility is not the only limiting factor influencing the activity, but also the intestinal permeability. TPGS-stabilized curcumin nanoparticles offer a solution for both absorption barriers. The benefit of improving bio-availability through nanotechnology is in minimizing the therapeutic dose as proven in this study. The issue of drug toxicity is, further, an important target in addition to efficacy, when the therapeutic dose of such drugs is decreased. So, the potency of the natural compound in therapy improved significantly by nanonization.

Acknowledgments: This project was co-funding between Deutscher Akademischer Austauschdienst (German Academic Exchange Service), under the scheme of the Indonesian–German Scientists Exchange Program and Bandung Institute of Technology under scheme of Innovation Research, 2012.

Author Contributions: Heni Rachmawati was responsible for the preparation and characterization of curcumin nanocrystal; Dewi Safitri and I Ketut Adnyana did animal experimentation; Aditya Trias Pradana studied biodistribution. All authors contributed in the manuscript writing.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Tonnesen, H.H.; Masson, M.; Loftsson, T. Studies of curcumin and curcumins, cyclodextrin complexation, solubility, chemical and photochemical stability. *Int. J. Pharm.* **2002**, *244*, 127–135. [CrossRef]
2. Jankun, J.; Aleem, A.M.; Malgorzewicz, S.; Szkudlarek, M.; Zavodszky, M.I.; Dewitt, D.L.; Feiq, M.; Selman, S.H.; Skrzypczak-Jankun, E. Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells. *Mol. Cancer Ther.* **2006**, *5*, 1371–1382. [CrossRef] [PubMed]
3. Fujisawa, S.; Atsumi, T.; Ishihara, M.; Kadoma, Y. Cytotoxicity, ROS generation activity and radical-scavenging activity of curcumin and related compounds. *Anticancer Res.* **2004**, *24*, 563–569. [PubMed]
4. Tomren, M.A.; Måsson, M.; Loftsson, T.; Tønnesen, H.H. Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: Stability, activity and complexation with cyclodextrin. *Int. J. Pharm.* **2007**, *338*, 27–34. [CrossRef] [PubMed]
5. Balasubramanian, K. Molecular orbital basis for yellow curry spice curcumin's prevention of Alzheimer's disease. *J. Agric. Food Chem.* **2006**, *54*, 3512–3520. [CrossRef] [PubMed]
6. Pan, M.H.; Miaohuang, T.; Kunlin, J. Biotransformation of curcumin through reduction and glucuronidation in mice. *Drug Metab. Dispos.* **1998**, *27*, 486–494.
7. Ravindranath, V.; Chandrasekhara, N. Absorption and tissue distribution of curcumin in rats. *Toxicology* **1980**, *16*, 259–265. [CrossRef]
8. Rachmawati, H.; Shaal, L.A.; Müller, R.H.; Keck, C.M. Development of curcumin nanoparticle: Physical aspects. *J. Pharm. Sci.* **2013**, *102*, 204–214. [CrossRef] [PubMed]
9. Vogel, H.G.; Vogel, W.H. *Drug Discovery and Evaluation: Pharmacological Assays*, 2nd ed.; Springer: Berlin, Germany, 2002; pp. 762–776.
10. Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int. J. Biochem. Cell Biol.* **2009**, *41*, 40–59. [CrossRef] [PubMed]
11. Morris, C.J. Carrageenan—Induced paw edema in the rat and mouse. In *Methods in Molecular Biology: Inflammation Protocols*; Winyard, P.G., Willoughby, D.A., Eds.; Humana Press Inc.: Totowa, NJ, USA, 2003; pp. 115–121.
12. Aggarwal, B.B.; Sundaram, C.; Malani, N.; Ichikawa, H. Curcumin: The Indian solid gold. In *The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease*; Springer: New York, NY, USA, 2007; pp. 1–75.
13. Lukita-Atmaja, W.; Yoshiya, I.; Gregory, L.B.; Robert, S.M. Effect of curcumin as anti-inflammatory agents on the hepatic microvascular response to endotoxin. *Shock* **2002**, *17*, 399–403. [CrossRef]
14. Huang, M.T.; Wei, M.; Ping, L.; Richard, L.C.; Carolyn, F.; Percy, S.M.; Harold, L.N.; Allan, H.C. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. *Carcinogenesis* **1995**, *16*, 2493–2497. [CrossRef] [PubMed]
15. Rubi, A.J.; Kuttan, G.; Babu, K.D.; Rajasekharan, K.N.; Kuttan, R. Antioxidant and antitumor activity of natural curcumin. *Cancer Lett.* **1995**, *94*, 79–83. [CrossRef]
16. Heger, M.; Golen, R.F.; Broekgaarden, M.; Michel, M.C. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. *Pharmacol. Rev.* **2013**, *66*, 222–307. [CrossRef] [PubMed]
17. Jeong, G.S.; Oh, G.S.; Pae, H.O.; Jeong, S.O.; Kim, Y.C.; Shin, M.K.; Seo, B.Y.; Han, S.Y.; Lee, H.S.; Jeong, J.G.; et al. Comparative effects of curcuminoids on endothelial heme oxygenase-1 expression: Ortho-methoxy groups are essential to enhance heme oxygenase activity and protection. *Exp. Mol. Med.* **2006**, *38*, 393–400. [CrossRef] [PubMed]





Search for Articles:

[Search](#)

[Advanced](#)

[Journals](#) / [Pharmaceutics](#)



pharmaceutics

Pharmaceutics

IMPACT
FACTOR
4.9

Indexed in
PubMed

CITESCORE
7.9

E-Mail Alert

Add your e-mail address to receive

Pharmaceutics

by Mengxiang Tian, Bingzhi Dong, Weiqi Li, Liying Wang and Hong Yu



Journal Description

Pharmaceutics is a [peer-reviewed](#), open access journal on the science and technology of pharmaceuticals and biopharmaceuticals, and is published monthly online by MDPI. [The Spanish Society of Pharmaceutics and Pharmaceutical Technology \(SEFIG\)](#), [Pharmaceutical Solid State Research Cluster \(PSSRC\)](#), [Academy of Pharmaceutical Sciences \(APS\)](#), and [Korean Society of Pharmaceutical Sciences and Technology \(KSPST\)](#) are affiliated with *Pharmaceutics* and their members receive a discount on the article processing charges.

- **Open Access**— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.
- **High Visibility**: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CABIplus / SciFinder](#), and [other databases](#).
- **Journal Rank**: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)
- **Rapid Publication**: manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).
- **Recognition of Reviewers**: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
- **Companion journals for *Pharmaceutics* include**: [Future Pharmacology](#) and [Journal of Pharmaceutical and BioTech Industry](#).

Impact Factor: 4.9 (2023); 5-Year Impact Factor: 5.5 (2023)

Latest Articles

29 pages, 2602 KiB

Open Access Systematic Review

[Recent Advances in the Drugs and Glucose-Responsive Drug Delivery Systems for the Treatment of Diabetes: A Systematic Review](#)

by Junyu Liu, Xudong Yi, Jinrui Zhang, Yiman Yao, Pharkphoom Panichayupakaranant and Haixia Chen

Pharmaceutics 2024, 16(10), 1343; <https://doi.org/10.3390/pharmaceutics16101343> (registering DOI) - 20 Oct 2024

[Abstract](#)

Diabetes is a common chronic metabolic disease. Different types of drugs play important roles in controlling diabetes and its complications, but there are some limitations. The glucose-responsive drug delivery system is a novel technology with potential in diabetes treatment. It could automatically release [...] [Read more](#).

Diabetes is a common chronic metabolic disease. Different types of drugs play important roles in controlling diabetes and its complications, but there are some limitations. The glucose-responsive drug delivery system is a novel technology with

Pharmaceutics



Editorial Board

Please note that the order in which the Editors appear on this page is alphabetical, and follows the structure of the editorial board presented on the MDPI website under information for editors: [editorial board responsibilities](#).

Members



Prof. Dr. Patrick J. Sinko

[Website](#)

Editor-in-Chief

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Interests: drug delivery; nanotechnology; biopharmaceutics; pharmacokinetics; absorption; permeability; AIDS; cancer

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Dimitrios A. Lamprou

*

[Website](#)

Section Editor-in-Chief

School of Pharmacy, Queen's University Belfast, Belfast BT7 1NN, UK

Interests: 3D printing; bioprinting; drug delivery; electrospinning; medical devices; pharmaceuticals; microfluidics

* Section: Physical Pharmacy and Formulation

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Francisco Javier Otero-Espinar

*

[Website](#)


Section Editor-in-Chief

Department of Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain

Interests: ocular drug delivery

* Section: Drug Delivery and Controlled Release

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Beom Soo Shin

*

[Website](#)

Section Editor-in-Chief

School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 16419, Republic of Korea

Interests: pharmacokinetics; translational PKPD modeling; PBPK modeling; in vitro–in vivo correlation; pharmaceutical analysis; 3D printing

* Section: Pharmacokinetics and Pharmacodynamics

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Thierry Vandamme

*

[Website](#)

Section Editor-in-Chief

Laboratory for the Conception and Application of Bioactive Molecules, Faculty of Pharmacy, University of Strasbourg, 67400 Illkirch-Graffenstaden, France

Interests: microencapsulation; nanoemulsions; biopharmacy; formulation; pharmaceutical engineering

* Section: Pharmaceutical Technology, Manufacturing and Devices

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Wei Wu

*

[Website](#)

Section Editor-in-Chief

Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China

Interests: drug delivery; pharmaceutics; oral delivery; controlled and sustained release; pharmaceutical technology

* Section: Nanomedicine and Nanotechnology

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Ruggero Bettini

[Website](#)

Associate Editor

Food and Drug Department, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy

Interests: supercritical fluids; solid state chemistry; particle and crystal engineering; oral delivery; polymeric scaffolds; powders for transmucosal and pulmonary drug delivery; industrial pharmacy



Prof. Dr. Afzal R. Mohammed

[Website](#)

Associate Editor

Aston Pharmacy School, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK

Interests: freeze drying; fast disintegrating tablets; reformulation of medicines; microarray

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Yvonne Perrie

[Website](#)

Advisory Board Member

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK

Interests: particulate systems and formulations for drug delivery; vaccine adjuvanticity and diagnostics

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Zeeshan Ahmad

[Website](#)

Editorial Board Member

Leicester School of Pharmacy, De Montfort University, The Gateway, Leicester LE1 9BH, UK

Interests: nanotechnology; pharmaceutical engineering; fibers; nanoparticles; manufacturing; biomaterials; dosage forms

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Raid Alany

[Website1](#) [Website2](#)

Editorial Board Member

1. Faculty of Science, Engineering and Computing, Kingston University London, Penrhyn Road, Kingston upon Thames, London KT1 2EE, UK

2. Faculty of Medical and Health Sciences, The University of Auckland, Auckland CBD, Auckland 1010, New Zealand

Interests: ophthalmic drugs and delivery systems; veterinary pharmaceuticals

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Göran Alderborn

[Website](#)

Editorial Board Member

Department of Pharmaceutical Biosciences, Uppsala University, 752 36 Uppsala, Sweden

Interests: formulation of tablets; formulation of inhalation powders; particle preparation and characterization; powder processing and characterization; stability of solid systems

Prof. Dr. António J. Almeida

[Website](#)

Editorial Board Member

Faculdade de Farmácia, Universidade de Lisboa, 1649-004 Lisboa, Portugal

Interests: drug delivery; microparticles; nanoparticles; mucosal delivery; mucosal vaccines

[grade Website](#)

Editorial Board Member

Department of Medicine and Medical Microbiology and Immunology, Head Division of Infectious Diseases, University of Wisconsin, 1685 Highland Ave, Madison, WI 53705-2281, USA

Interests: antimicrobial pharmacokinetics and pharmacodynamics; antimicrobial drug development; antimicrobial resistance



Dr. Anna Angela Barba

[Website](#)

Editorial Board Member

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy

Interests: drug delivery systems; sustainable process; process intensification; micro/nano fabrication techniques; liposomes production; hydrogels

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Sophia G. Antimisiaris

[Website](#)

Editorial Board Member

1. Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Rio-Patras, Greece

2. Institute for Chemical Engineering Sciences, Foundation for Research and Technology Hellas, FORTH/ICE-HT, Stadiou Street, 26510 Platani-Rio, Greece

Interests: targeted drug delivery; nanomedicines; liposome technology; lipid-based formulations

[Special Issues, Collections and Topics in MDPI journals](#)

Prof. Dr. Jessie Lai Sim Au

[Website](#)

Editorial Board Member

Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA

Interests: cancer treatments; Quantitative Systems Pharmacology; clinical drug development



Prof. Dr. Ildiko Badea

[Website](#)

Editorial Board Member

College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Health Sciences Building, Room 3D01.5, Box 3D01-13, Saskatoon, SK S7N 5E5, Canada

Interests: nucleic acid delivery; nanodiamonds; cationic gemini lipids; self-assembling nanoparticles; small angle X-ray scattering; flow cytometry; radiopharmaceuticals

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Juan J. Badimon

[Website](#)

Editorial Board Member

AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA

Interests: thrombosis platelet; antiplatelets and anticoagulants; cardiovascular disease; lipid and lipid-lowering agents; diabetes; SGLT2-inhibitors



Prof. Dr. Udo Bakowsky

[Website](#)

Editorial Board Member

Department of Pharmaceutics and Biopharmaceutics, University of Marburg, Robert-Koch-Str. 4, 35037 Marburg, Germany

Interests: nanoscale drug delivery systems; photodynamic therapy; liposomes; gene therapy

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Ajay K. Banga

[Website](#)

Editorial Board Member

Center for Drug Delivery and Research, Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA

Interests: transdermal delivery; topical delivery; iontophoresis; sonophoresis; laser assisted percutaneous delivery; microdermabrasion; microneedles



Prof. Dr. Arvind K. Bansal

[Website](#)

Editorial Board Member

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar (Mohali), Punjab 160 062, India

Interests: pre-formulation profiling; solid state characterization; polymorphism; amorphous systems; particle engineering; nano-crystalline dispersions; enhancement of oral bioavailability

[Special Issues, Collections and Topics in MDPI journals](#)



Prof. Dr. Antonello A. Barresi

[Website](#)

Editorial Board Member

Coordinator of Pharmaceutical Technology lab, Department of Applied Science and Technology, Politecnico di Torino, 24 Corso Duca degli Abruzzi, 10129 Torino, Italy

Interests: freeze-drying; process monitoring; drug release; nanocarriers

[Special Issues, Collections and Topics in MDPI journals](#)

[grade Website](#)

Editorial Board Member

Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29/39 Brunswick Square, London WC1N 1AX, UK

Interests: biopharmaceutics; physiology of the gastrointestinal tract; formulation and modified release; oral drug delivery; colonic targeting; drug metabolism; drug absorption; gamma scintigraphy

[Special Issues, Collections and Topics in MDPI journals](#)



Dr. Elena V. Batrakova

[Website](#)

Editorial Board Member

Center for Nanotechnology in Drug Delivery, Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, MARSICO HALL, 125 Mason Farm Road, Chapel Hill, NC 27599-7362, USA

Interests: cell-mediated and exosome-mediated drug delivery systems; neurodegenerative disorders; Parkinson's disease; Lysosomal storage disorders, Batten disease

Prof. Dr. Luigi Battaglia

[Website](#)

Editorial Board Member

Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, via Pietro Giuria 9, 10125 Torino, Italy

Interests: solid lipid nanoparticles (SLN); nanoemulsions; protein nano delivery systems

Prof. Dr. Richard A. Beers

[Website](#)

Editorial Board Member

Department of Anesthesiology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA

Interests: anesthetics (inhaled and intravenous); opioids; anti-emetics; neuromuscular blocking agents; sympathomimetics; sympatholytics; parasympatholytics; cholinesterase inhibitors

Prof. Dr. Francine Behar-Cohen

[Website](#)

Editorial Board Member

1. Eyevensys, 11 Rue Watt, 75013 Paris, France
2. Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, From Physiopathology of Ocular Diseases to Clinical Development, 75006 Paris, France
3. Cochin Hospital, AP-HP, Assistance Publique Hôpitaux de Paris, 24 rue du Faubourg Saint Jacques, 75014 Paris, France

Interests: neuroprotection; diabetic retinopathy; retinal ischemia; glia; drug development

[Special Issues, Collections and Topics in MDPI journals](#)



Dr. Heather Benson

[Website](#)

Editorial Board Member

School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, GPO Box U 1987, Perth, WA 6845, Australia

Interests: topical and transdermal drug delivery; penetration enhancement; nanotechnology; skin permeation mechanisms

[Special Issues, Collections and Topics in MDPI journals](#)

[Sign In / Sign Up \(/user/login\)](#)[Submit \(https://susy.mdpi.com/user/manuscripts/upload?journal=pharmaceutics\)](https://susy.mdpi.com/user/manuscripts/upload?journal=pharmaceutics)

Search for Articles:

Advanced Search

[Journals \(/about/journals\)](#) / [Pharmaceutics \(/journal/pharmaceutics\)](#) / [Volume 8 \(/1999-2020\)](#) / [Issue 3 /](#)



pharmaceutics [\(/journal/pharmaceutics\)](#)

[Submit to Pharmaceutics \(https://susy.mdpi.com/user/manuscripts/upload?journal=pharmaceutics\)](#)

[Review for Pharmaceutics \(https://susy.mdpi.com/user/manuscripts/upload?journal=pharmaceutics\)](#)

CITESCORE

7.9

<https://www.scopus.com/sourceid/19700188360>

Journal Menu

[Journal Menu](#)

**Indexed in:
PubMed**

<https://www.ncbi.nlm.nih.gov/pubmed/?term=1999-4923>



- [Pharmaceutics Home \(/journal/pharmaceutics\)](/journal/pharmaceutics)
- [MDPI Arms & Scope \(/journal/pharmaceutics/about\)](/journal/pharmaceutics/about)
- [Editorial Board \(/journal/pharmaceutics/editors\)](/journal/pharmaceutics/editors)
- [Reviewer Board \(/journal/pharmaceutics/submission_reviewers\)](/journal/pharmaceutics/submission_reviewers)
- [Topical Advisory Panel \(/journal/pharmaceutics/topical_advisory_panel\)](/journal/pharmaceutics/topical_advisory_panel)
- [Instructions for Authors \(/journal/pharmaceutics/instructions\)](/journal/pharmaceutics/instructions)
- [Special Issues \(/journal/pharmaceutics/special_issues\)](/journal/pharmaceutics/special_issues)
- [Topics \(/topics?journal=pharmaceutics\)](/topics?journal=pharmaceutics)
- [Sections & Collections \(/journal/pharmaceutics/sections\)](/journal/pharmaceutics/sections)
- [Article Processing Charge \(/journal/pharmaceutics/apc\)](/journal/pharmaceutics/apc)
- [Indexing & Archiving \(/journal/pharmaceutics/indexing\)](/journal/pharmaceutics/indexing)
- [Editor's Choice Articles \(/journal/pharmaceutics/editors_choice\)](/journal/pharmaceutics/editors_choice)
- [Most Cited & Viewed \(/journal/pharmaceutics/most_cited\)](/journal/pharmaceutics/most_cited)
- [Journal Statistics \(/journal/pharmaceutics/stats\)](/journal/pharmaceutics/stats)
- [Journal History \(/journal/pharmaceutics/history\)](/journal/pharmaceutics/history)
- [Journal Awards \(/journal/pharmaceutics/awards\)](/journal/pharmaceutics/awards)
- [Society Collaborations \(/journal/pharmaceutics/societies\)](/journal/pharmaceutics/societies)
- [Conferences \(/journal/pharmaceutics/events\)](/journal/pharmaceutics/events)
- [Editorial Office \(/journal/pharmaceutics/editorial_office\)](/journal/pharmaceutics/editorial_office)



IMPACT FACTOR 4.9

(/journal/pharmaceutics/stats)

Journal Browser

► Journal Browser

- › [Forthcoming issue \(/1999-4923/16/10\)](/1999-4923/16/10)
- › [Current issue \(/1999-4923/16/9\)](/1999-4923/16/9)

- [Vol. 16 \(2024\) \(/1999-4923/16\)](/1999-4923/16)
- [Vol. 15 \(2023\) \(/1999-4923/15\)](/1999-4923/15)
- [Vol. 14 \(2022\) \(/1999-4923/14\)](/1999-4923/14)
- [Vol. 13 \(2021\) \(/1999-4923/13\)](/1999-4923/13)
- [Vol. 12 \(2020\) \(/1999-4923/12\)](/1999-4923/12)
- [Vol. 11 \(2019\) \(/1999-4923/11\)](/1999-4923/11)
- [Vol. 10 \(2018\) \(/1999-4923/10\)](/1999-4923/10)
- [Vol. 9 \(2017\) \(/1999-4923/9\)](/1999-4923/9)
- [Vol. 8 \(2016\) \(/1999-4923/8\)](/1999-4923/8)
- [Vol. 7 \(2015\) \(/1999-4923/7\)](/1999-4923/7)
- [Vol. 6 \(2014\) \(/1999-4923/6\)](/1999-4923/6)
- [Vol. 5 \(2013\) \(/1999-4923/5\)](/1999-4923/5)
- [Vol. 4 \(2012\) \(/1999-4923/4\)](/1999-4923/4)
- [Vol. 3 \(2011\) \(/1999-4923/3\)](/1999-4923/3)
- [Vol. 2 \(2010\) \(/1999-4923/2\)](/1999-4923/2)
- [Vol. 1 \(2009\) \(/1999-4923/1\)](/1999-4923/1)

Affiliated Society:



https://serve.mdpi.com/www/my_files/cliik.php?oaparams=0bannerid=6103zone

[Back to Top](#)

- Issues are regarded as officially published after their release is announced to the [table of contents alert mailing list \(/journal/pharmaceutics/toc-alert\)](#).
- You may [sign up for e-mail alerts \(/journal/pharmaceutics/toc-alert\)](#) to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free [Adobe Reader \(http://www.adobe.com/\)](http://www.adobe.com/) to open them.

Order results

Publication Date

Result details

Normal

Section

All Sections

[Show export options](#)

Open Access Article

1963 KiB [./1999-4923/8/3/29/pdf?version=1473740397](#)

[Rapid Quantification and Validation of Lipid Concentrations within Liposomes \(/1999-4923/8/3/29\)](#)

by **Carla B. Roces, Elisabeth Kastner, Peter Stone, Deborah Lowry and Yvonne Perrie**

Pharmaceutics 2016, 8(3), 29; <https://doi.org/10.3390/pharmaceutics8030029> (<https://doi.org/10.3390/pharmaceutics8030029>) - 13 Sep 2016

[Cited by 29 \(/1999-4923/8/3/29#metrics\)](#) | Viewed by 9178

Abstract Quantification of the lipid content in liposomal adjuvants for subunit vaccine formulation is of extreme importance, since this concentration impacts both efficacy and stability. In this paper, we outline a high performance liquid chromatography-evaporative light scattering detector (HPLC-ELSD) method that allows for the [...] [Read more.](#)

(This article belongs to the Special Issue [Liposome Technologies 2015 \(/journal/pharmaceutics/special_issues/liposome_technologies_2015\)](#).)

► [Show Figures](#)

https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029/article_deploy/html/images/pharmaceutics-08-00029-ag-550.gif?1581083648 ([https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029-g001-1024.png?1473740482](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029/article_deploy/html/images/pharmaceutics-08-00029-g001-1024.png?1473740482)) ([https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029-g002-1024.png?1473740482](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029/article_deploy/html/images/pharmaceutics-08-00029-g002-1024.png?1473740482)) ([https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029-g003-1024.png?1473740482](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029/article_deploy/html/images/pharmaceutics-08-00029-g003-1024.png?1473740482)) ([https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029-g004-1024.png?1473740482](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029/article_deploy/html/images/pharmaceutics-08-00029-g004-1024.png?1473740482)) ([https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029-g005-1024.png?1473740482](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029/article_deploy/html/images/pharmaceutics-08-00029-g005-1024.png?1473740482)) ([https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029-g006-1024.png?1473740482](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00029/article_deploy/html/images/pharmaceutics-08-00029-g006-1024.png?1473740482))

Open Access Article

895 KiB [./1999-4923/8/3/28/pdf?version=1472725720](#)

[An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems \(/1999-4923/8/3/28\)](#)

by **Dileep R. Janagam, Lizhu Wang, Suryatheja Ananthula, James R. Johnson and Tao L. Lowe**

Pharmaceutics 2016, 8(3), 28; <https://doi.org/10.3390/pharmaceutics8030028> (<https://doi.org/10.3390/pharmaceutics8030028>) - 1 Sep 2016

Cited by 20 ([/1999-4923/8/3/28#metrics](#)) | Viewed by 7182

Abstract Biodegradable polymer-based injectable in situ forming depot (ISD) systems that solidify in the body to form a solid or semisolid reservoir are becoming increasingly attractive as an injectable dosage form for sustained (months to years) parenteral drug delivery. Evaluation of long-term drug release [...] [Read more.](#)

► [Show Figures](#)

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00028/article_deploy/html/images/pharmaceutics-08-00028-ag-1024.png?1472725796) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00028/article_deploy/html/images/pharmaceutics-08-00028-g001-1024.png?1472725796) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00028/article_deploy/html/images/pharmaceutics-08-00028-g002-1024.png?1472725796) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00028/article_deploy/html/images/pharmaceutics-08-00028-g003-1024.png?1472725796) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00028/article_deploy/html/images/pharmaceutics-08-00028-g004-1024.png?1472725796)

Open Access Article

13753 KiB

[/1999-4923/8/3/27/pdf?version=1472641141](#)

[Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder \(\[/1999-4923/8/3/27\]\(#\)\)](#)

by Rajan Rajabalaya, Guok Leen, Jestin Chellian, Srikumar Chakravarthi and Sheba R. David

Pharmaceutics 2016, 8(3), 27; <https://doi.org/10.3390/pharmaceutics8030027> (<https://doi.org/10.3390/pharmaceutics8030027>) - 31 Aug 2016

Cited by 30 ([/1999-4923/8/3/27#metrics](#)) | Viewed by 5952

Abstract The goal of this study was to formulate and evaluate side effects of transdermal delivery of proniosomal gel compared to oral tolterodine tartrate (TT) for the treatment of overactive bladder (OAB). Proniosomal gels are surfactants, lipids and soy lecithin, prepared by coacervation phase [...] [Read more.](#)

► [Show Figures](#)

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00027/article_deploy/html/images/pharmaceutics-08-00027-ag-1024.png?1472641229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00027/article_deploy/html/images/pharmaceutics-08-00027-g001-1024.png?1472641229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00027/article_deploy/html/images/pharmaceutics-08-00027-g002a-1024.png?1472641229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00027/article_deploy/html/images/pharmaceutics-08-00027-g002b-1024.png?1472641230) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00027/article_deploy/html/images/pharmaceutics-08-00027-g003-1024.png?1472641229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00027/article_deploy/html/images/pharmaceutics-08-00027-g004-1024.png?1472641229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00027/article_deploy/html/images/pharmaceutics-08-00027-g005-1024.png?1472641229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00027/article_deploy/html/images/pharmaceutics-08-00027-g006-1024.png?1472641229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00027/article_deploy/html/images/pharmaceutics-08-00027-g007a-1024.png?1472641229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00027/article_deploy/html/images/pharmaceutics-08-00027-g007b-1024.png?1472641230)

Open Access Review

820 KiB

[/1999-4923/8/3/26/pdf?version=1472555949](#)

[Performance Parameters and Characterizations of Nanocrystals: A Brief Review \(\[/1999-4923/8/3/26\]\(#\)\)](#)

by Manasi M. Chogale, Vinod N. Ghodake and Vandana B. Patravale

Pharmaceutics 2016, 8(3), 26; <https://doi.org/10.3390/pharmaceutics8030026> (<https://doi.org/10.3390/pharmaceutics8030026>) - 30 Aug 2016

Cited by 58 ([/1999-4923/8/3/26#metrics](#)) | Viewed by 6168

Abstract Poor bioavailability of drugs associated with their poor solubility limits the clinical effectiveness of almost 40% of the newly discovered drug moieties. Low solubility, coupled with a high log p value, high melting point and high dose necessitates

[Back to Top](#)

exploration of alternative formulation strategies [...] [Read more.](#)

(This article belongs to the Special Issue [Nanocrystals \(/journal/pharmaceutics/special_issues/nanocrystals\)](#))

► [Show Figures](#)

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00026/article_deploy/html/images/pharmaceutics-08-00026-g001-1024.png?1472556019) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00026/article_deploy/html/images/pharmaceutics-08-00026-g002-1024.png?1472556019) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00026/article_deploy/html/images/pharmaceutics-08-00026-g003-1024.png?1472556019)

Open Access Article

944 KiB

(/1999-4923/8/3/25/pdf?version=1472203983)

[Influence of the Encapsulation Efficiency and Size of Liposome on the Oral Bioavailability of Griseofulvin-Loaded Liposomes \(/1999-4923/8/3/25\)](#)

by **Sandy Gim Ming Ong, Long Chiau Ming, Kah Seng Lee and Kah Hay Yuen**

Pharmaceutics **2016**, *8*(3), 25; <https://doi.org/10.3390/pharmaceutics8030025> (<https://doi.org/10.3390/pharmaceutics8030025>) - 26 Aug 2016

Cited by 158 (/1999-4923/8/3/25#metrics) | Viewed by 11220

Abstract The objective of the present study was to investigate the influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Griseofulvin-loaded liposomes with desired characteristics were prepared from pro-liposome using various techniques. To study the effect of [...] [Read more.](#)

(This article belongs to the Special Issue [Liposome Technologies 2015 \(/journal/pharmaceutics/special_issues/liposome_technologies_2015\)](#))

► [Show Figures](#)

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00025/article_deploy/html/images/pharmaceutics-08-00025-g001-1024.png?1472205577) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00025/article_deploy/html/images/pharmaceutics-08-00025-g002-1024.png?1472205577) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00025/article_deploy/html/images/pharmaceutics-08-00025-g003-1024.png?1472205577)

Open Access Article

5766 KiB

(/1999-4923/8/3/24/pdf?version=1471349629)

[TPGS-Stabilized Curcumin Nanoparticles Exhibit Superior Effect on Carrageenan-Induced Inflammation in Wistar Rat \(/1999-4923/8/3/24\)](#)

by **Heni Rachmawati, Dewi Safitri, Aditya Trias Pradana and I Ketut Adnyana**

Pharmaceutics **2016**, *8*(3), 24; <https://doi.org/10.3390/pharmaceutics8030024> (<https://doi.org/10.3390/pharmaceutics8030024>) - 16 Aug 2016


Cited by 17 (/1999-4923/8/3/24#metrics) | Viewed by 8804

Abstract Curcumin, a hydrophobic polyphenol compound derived from the rhizome of the *Curcuma* genus, has a wide spectrum of biological and pharmacological applications. Previously, curcumin nanoparticles with different stabilizers had been produced successfully in order to enhance solubility and per oral absorption. In the [...] [Read more.](#)

(This article belongs to the Special Issue [Nanocrystals \(/journal/pharmaceutics/special_issues/nanocrystals\)](#))

► [Show Figures](#)

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g001-1024.png?1471349737) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g002-1024.png?1471349737) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g003-1024.png?1471349737) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g004-1024.png?1471349737) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g005-1024.png?1471349737) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g006-1024.png?1471349737) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g007-1024.png?1471349737)

 [g008-1024.png?1471349737](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g008-1024.png?1471349737)) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g008-1024.png?1471349737) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g009-1024.png?1471349737) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00024/article_deploy/html/images/pharmaceutics-08-00024-g010-1024.png?1471349737)

Open Access Review

1129 KiB

[\(/1999-4923/8/3/23/pdf?version=1469099429\)](#)

Drug Delivery Approaches for the Treatment of Cervical Cancer ([/1999-4923/8/3/23](#))

by Farideh Ordikhani, Mustafa Erdem Arslan, Raymundo Marcelo, Ilyas Sahin, Perry Grigsby, Julie K. Schwarz and Abdel Kareem Azab

Pharmaceutics **2016**, *8*(3), 23; <https://doi.org/10.3390/pharmaceutics8030023> (<https://doi.org/10.3390/pharmaceutics8030023>) - 20 Jul 2016

Cited by 66 ([/1999-4923/8/3/23#metrics](#)) | Viewed by 10567

Abstract Cervical cancer is a highly prevalent cancer that affects women around the world. With the availability of new technologies, researchers have increased their efforts to develop new drug delivery systems in cervical cancer chemotherapy. In this review, we summarized some of the recent [...] **Read more.**

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00023/article_deploy/html/images/pharmaceutics-08-00023-ag-550.jpg?1581073273) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00023/article_deploy/html/images/pharmaceutics-08-00023-g001-1024.png?1469099508) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00023/article_deploy/html/images/pharmaceutics-08-00023-g002-1024.png?1469099508) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00023/article_deploy/html/images/pharmaceutics-08-00023-g003-1024.png?1469099508)

Open Access Article

1183 KiB

[\(/1999-4923/8/3/22/pdf?version=1468823357\)](#)

2-O-Acyl-3-O-(1-acyloxyalkyl) Prodrugs of 5,6-Isopropylidene-L-Ascorbic Acid and L-Ascorbic Acid: Antioxidant Activity and Ability to Permeate Silicone Membranes ([/1999-4923/8/3/22](#))

by Nikki A. Thiele, Jennifer McGowan and Kenneth B. Sloan

Pharmaceutics **2016**, *8*(3), 22; <https://doi.org/10.3390/pharmaceutics8030022> (<https://doi.org/10.3390/pharmaceutics8030022>) - 18 Jul 2016

Cited by 2 ([/1999-4923/8/3/22#metrics](#)) | Viewed by 5886

Abstract 2-O-Acyl-3-O-(1-acyloxyalkyl) prodrug derivatives, **15**, of 5,6-isopropylidene-L-ascorbic acid, **VCA**, and L-ascorbic acid, **VC**, have been characterized by measuring (1) their solubilities in water (S_{AQ}) and in 1-octanol (S_{OCT}); (2) the [...] **Read more.**

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00022/article_deploy/html/images/pharmaceutics-08-00022-g001-550.jpg?1475056914) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00022/article_deploy/html/images/pharmaceutics-08-00022-g002-550.jpg?1475056914) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00022/article_deploy/html/images/pharmaceutics-08-00022-g003-550.jpg?1475056914) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00022/article_deploy/html/images/pharmaceutics-08-00022-g004-550.jpg?1475056914) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00022/article_deploy/html/images/pharmaceutics-08-00022-g005-550.jpg?1475056914) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00022/article_deploy/html/images/pharmaceutics-08-00022-sch001-550.jpg?1475056914) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00022/article_deploy/html/images/pharmaceutics-08-00022-sch002-550.jpg?1475056914)

 Access Article

1800 KiB

[\(/1999-4923/8/3/21/pdf?version=1467893227\)](#)

Back to TopTop

Investigation of the Dermal Absorption and Irritation Potential of Sertaconazole Nitrate Anhydrous Gel

(/1999-4923/8/3/21)

by Mahima Manian, Kumpal Madrasi, Ayyappa Chaturvedula and Ajay K. Banga

Pharmaceutics 2016, 8(3), 21; <https://doi.org/10.3390/pharmaceutics8030021> (<https://doi.org/10.3390/pharmaceutics8030021>) - 7 Jul 2016

Cited by 7 (/1999-4923/8/3/21#metrics) | Viewed by 5734

Abstract Effective topical therapy of cutaneous fungal diseases requires the delivery of the active agent to the target site in adequate concentrations to produce a pharmacological effect and inhibit the growth of the pathogen. In addition, it is important to determine the concentration of [...] [Read more.](#)

► [Show Figures](#)

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00021/article_deploy/html/images/pharmaceutics-08-00021-g001-550.jpg?1475056903) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00021/article_deploy/html/images/pharmaceutics-08-00021-g002-550.jpg?1475056903) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00021/article_deploy/html/images/pharmaceutics-08-00021-g003-550.jpg?1475056903) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00021/article_deploy/html/images/pharmaceutics-08-00021-g004-550.jpg?1475056903) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00021/article_deploy/html/images/pharmaceutics-08-00021-g005a-550.jpg?1475056903) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00021/article_deploy/html/images/pharmaceutics-08-00021-g005b-550.jpg?1475056903) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00021/article_deploy/html/images/pharmaceutics-08-00021-g006-550.jpg?1475056903) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00021/article_deploy/html/images/pharmaceutics-08-00021-g007-550.jpg?1475056903)

Open Access Article

9210 KiB (/1999-4923/8/3/20/pdf?version=1467032305)

Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation (/1999-4923/8/3/20)

by Ali Nasr, Ahmed Gardouh and Mamdouh Ghorab

Pharmaceutics 2016, 8(3), 20; <https://doi.org/10.3390/pharmaceutics8030020> (<https://doi.org/10.3390/pharmaceutics8030020>) - 27 Jun 2016


Cited by 173 (/1999-4923/8/3/20#metrics) | Viewed by 12045

Abstract The main purpose of this study was to develop a solid self-nanoemulsifying drug delivery system (S-SNEDDS) of Olmesartan (OLM) for enhancement of its solubility and dissolution rate. In this study, liquid SNEDDS containing Olmesartan was formulated and further developed into a solid form [...] [Read more.](#)

► [Show Figures](#)

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g001-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g002-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g003-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g004-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g005a-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g005b-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g006-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g007-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g008-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g009-1024.png?1467032426)



 [g009-1024.png?1467032426](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g010-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g010-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g011-1024.png?1467032426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-08-00020/article_deploy/html/images/pharmaceutics-08-00020-g012-1024.png?1467032426)

[Show export options](#)

Displaying articles 1-10

[Previous Issue](#)

[Volume 8, June \(/1999-4923/8/2\)](#)

[Next Issue](#)

[Volume 8, December \(/1999-4923/8/4\)](#)

[Pharmaceutics \(/journal/pharmaceutics\)](#), EISSN 1999-4923, Published by MDPI

[RSS \(/rss/journal/pharmaceutics\)](#) [Content Alert \(/journal/pharmaceutics/toc-alert\)](#)

Further Information

[Article Processing Charges \(/apc\)](#)

[Pay an Invoice \(/about/payment\)](#)

[Open Access Policy \(/openaccess\)](#)

[Contact MDPI \(/about/contact\)](#)

[Jobs at MDPI \(https://careers.mdpi.com\)](https://careers.mdpi.com)

Guidelines

[For Authors \(/authors\)](#)

[For Reviewers \(/reviewers\)](#)

[For Editors \(/editors\)](#)

[For Librarians \(/librarians\)](#)

[For Publishers \(/publishing_services\)](#)

[For Societies \(/societies\)](#)

[For Conference Organizers \(/conference_organizers\)](#)

MDPI Initiatives

[Sciforum \(https://sciforum.net\)](https://sciforum.net)

[MDPI Books \(https://www.mdpi.com/books\)](https://www.mdpi.com/books)

[Preprints.org \(https://www.preprints.org\)](https://www.preprints.org)

[Scilit \(https://www.scilit.net\)](https://www.scilit.net)

[SciProfiles \(https://sciprofiles.com?utm_source=mpdi.com&utm_medium=bottom_menu&utm_campaign=initiative\)](https://sciprofiles.com?utm_source=mpdi.com&utm_medium=bottom_menu&utm_campaign=initiative)

[Encyclopedia \(https://encyclopedia.pub\)](https://encyclopedia.pub)

[JAMS \(https://jams.pub\)](https://jams.pub)

[Proceedings Series \(/about/proceedings\)](#)

Follow MDPI

[LinkedIn \(https://www.linkedin.com/company/mdpi\)](https://www.linkedin.com/company/mdpi)

[Facebook \(https://www.facebook.com/MDPIOpenAccessPublishing\)](https://www.facebook.com/MDPIOpenAccessPublishing)

 [Twitter \(https://twitter.com/MDPIOpenAccess\)](https://twitter.com/MDPIOpenAccess)

[Back to Top](#)



Subscribe to receive issue release notifications and newsletters from MDPI journals

[./toggle_desktop_layout_cookie](#) 🔍 ☰

© 1996-2024 MDPI (Basel, Switzerland) unless otherwise stated

[Disclaimer](#)

[Terms and Conditions \(/about/terms-and-conditions\)](#)

[Privacy Policy \(/about/privacy\)](#)




[Back to Top](#)

Pharmaceutics

COUNTRY

Switzerland

 Universities and research institutions in Switzerland

 Media Ranking in Switzerland

SUBJECT AREA AND CATEGORY

Pharmacology, Toxicology and
Pharmaceutics
Pharmaceutical Science

PUBLISHER

Multidisciplinary Digital Publishing Institute (MDPI)

H-INDEX

106

PUBLICATION TYPE

Journals

ISSN

19994923

COVERAGE

2009-2023

INFORMATION

[Homepage](#)

[How to publish in this journal](#)


yvonne.perrie@strath.ac.uk

SCOPE

Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the [science](#) and technology of pharmaceuticals and biopharmaceuticals. It publishes reviews, regular research papers, communications, opinions, commentaries, and short notes. Covered topics include pharmaceutical formulation, process development, drug delivery, pharmacokinetics, biopharmaceutics, pharmacogenetics, and interdisciplinary research involving, but not limited to, engineering, biomedical sciences, and cell biology. Our aim is to encourage scientists to publish their experimental results and theoretical assumptions in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. In addition, this journal presents the following unique features: Manuscripts regarding research proposals and research ideas will be particularly welcomed. Computed data or files regarding the full details of the experimental procedures can be deposited as supplementary material if it is not possible to publish them in the Material and Methods section, as usual. We also accept manuscripts addressed to a broader audience, regarding research projects financed by public funds.

 Join the conversation about this journal

<p>1 Journal of Drug Targeting GBR 80%</p>	<p>2 Therapeutic Delivery GBR 80%</p>	<p>3 Drug Delivery and Translational Research USA 79%</p>	<p>4 OpenNano USA 79%</p>	<p>5 Expert Opinion on Drug Delivery GBR 78%</p>
--	---	---	---	--



Pharmaceutics

Q1 Pharmaceutical Science
best quartile

SJR 2023 0.89

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

``

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.

Metrics based on Scopus® data as of March 2024

N nita 4 years ago

hello,
how much percent plagiarism is accepted?

reply

Melanie Ortiz 4 years ago

Dear Nita,
thank you for contacting us.

SCImago Team

We are sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus. Unfortunately, we cannot help you with your request, we suggest you visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply. Best Regards, SCImago Team

F **forouzan** 5 years ago

Im pharmacy student

reply



Melanie Ortiz 5 years ago

SCImago Team

Dear user, thanks for your participation! Best Regards, SCImago Team

Leave a comment

Name

Email

(will not be published)


Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2024. Data Source: Scopus®

EST MODUS IN REBUS
Horatio (Saturne 1, 1, 104)

[Legal Notice](#)

[Privacy Policy](#)



Source details

Pharmaceutics

Open Access ⓘ

Years currently covered by Scopus: from 2009 to 2024

Publisher: Multidisciplinary Digital Publishing Institute (MDPI)

E-ISSN: 1999-4923

Subject area: [Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science](#)

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

CiteScore 2023

7.9 ⓘ

SJR 2023

0.892 ⓘ

SNIP 2023

1.005 ⓘ

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

CiteScore 2023 ▾

$$7.9 = \frac{70,829 \text{ Citations } 2020 - 2023}{8,912 \text{ Documents } 2020 - 2023}$$

Calculated on 05 May, 2024

CiteScoreTracker 2024 ⓘ

$$8.8 = \frac{78,176 \text{ Citations to date}}{8,888 \text{ Documents to date}}$$

Last updated on 05 October, 2024 • Updated monthly

CiteScore rank 2023 ⓘ

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#32/183	82nd
Pharmaceutical Science		

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)

About Scopus

[What is Scopus](#)
[Content coverage](#)
[Scopus blog](#)
[Scopus API](#)
[Privacy matters](#)

Language

[日本語版を表示する](#)
[查看简体中文版本](#)
[查看繁體中文版本](#)
[Просмотр версии на русском языке](#)

Customer Service

[Help](#)
[Tutorials](#)
[Contact us](#)

ELSEVIER

[Terms and conditions](#) [Privacy policy](#) [Cookies settings](#)

All content on this site: Copyright © 2024 Elsevier B.V. [↗](#), its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies [↗](#).

